scholarly journals Challenges Associated with Managing End-Stage Renal Disease in Extremely Morbid Obese Patients: Case Series and Literature Review

Nephron ◽  
2017 ◽  
Vol 137 (3) ◽  
pp. 172-177
Author(s):  
Faruk Turgut ◽  
Emaad M. Abdel-Rahman
Keyword(s):  
Literature Review ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Case Series ◽  
Obese Patients ◽  
Morbid Obese ◽  
Stage Renal Disease ◽  
End Stage

Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis

2018 ◽  
Vol 30 (2) ◽  
pp. 181-187 ◽  
Author(s):  
Sarah M Michienzi ◽  
Christopher A Schriever ◽  
Melissa E Badowski
Keyword(s):  
Human Immunodeficiency Virus ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Case Series ◽  
Drug Discontinuation ◽  
Immunodeficiency Virus ◽  
Before And After ◽  
Clinically Significant ◽  
Stage Renal Disease ◽  
End Stage

No single-tablet antiretroviral (ARV) regimens (STRs) are approved for patients with human immunodeficiency virus (HIV) and end-stage renal disease (ESRD) on hemodialysis (HD). Based on known pharmacokinetic (PK) properties, abacavir (ABC)/lamivudine (3TC)/dolutegravir (DTG) STR may represent a promising option. This case series presents the safety and efficacy of ABC/3TC/DTG STR in patients with HIV and ESRD on HD. Patients were included if they were HIV-positive, maintained on intermittent HD for ESRD, switched to an ARV regimen containing ABC/3TC/DTG, and had at least one set of virologic data before and after the switch. Average age (±standard deviation) was 59 (±8) years. The majority of patients were cis-gender male and non-Hispanic Black. Only one demonstrated clinically significant resistance at baseline. All were on multiple-tablet regimens prior to the switch. Five patients (83%) achieved undetectable HIV-RNA after the switch while only four patients (46%) were undetectable immediately prior. No decline in immune function was noted. ABC/3TC/DTG STR was well tolerated. Only one patient self-reported an adverse event (nausea), which resolved without drug discontinuation. Based on these data, it appears that ABC/3TC/DTG may be a safe and effective ARV-STR option for patients with HIV and ESRD on HD. A larger trial including a PK analysis is needed to confirm these findings.

Formal literature review of quality-of-life instruments used in end-stage renal disease

2000 ◽  
Vol 36 (2) ◽  
pp. 327-336 ◽  
Author(s):  
Kathleen A. Cagney ◽  
Albert W. Wu ◽  
Nancy E. Fink ◽  
Mollie W. Jenckes ◽  
Klemens B. Meyer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Literature Review ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Quality Of Life Instruments

Tolerability of Dose Escalation of Ibandronate in Patients with Multiple Myeloma and End-Stage Renal Disease: A Case Series

Onkologie ◽  
2009 ◽  
Vol 32 (8-9) ◽  
pp. 482-486 ◽  
Author(s):  
Dirk M. Henrich ◽  
Martin Hoffmann ◽  
Michael Uppenkamp ◽  
Raoul Bergner
Keyword(s):  
Multiple Myeloma ◽  
Renal Disease ◽  
Dose Escalation ◽  
End Stage Renal Disease ◽  
Case Series ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document